ANNUAL REPORT 2007 | 2008 - Gimv

More documents

Recommendations

Info

PORTFOLIO AND EQUITY EQUITY (LIMITED CONSOLIDATION) Financial assets valued at fair value through P&L (I) 737 935 of which listed shareholdings Company Bloombergsymbol Shareholding in % Shareholding in no. of shares Bid price in local currency Value (in EUR 000) Ablynx 1 ABLX BB 10.2% 3 703 483 5.70 20 751 Alfacam ALFA BB 3.2% 255 282 12.30 3 140 Avalon Pharmaceuticals AVRX US 5.3% 891 607 2.26 1 274 Barco BAR BB 9.9% 1 249 921 45.35 56 684 Evotec EVT GR 0.5% 360 238 1.70 612 Galapagos GLPG BB 0.4% 87 940 5.91 520 Innate Pharma IPH FP 7.6% 1 925 020 2.03 3 908 LivePerson LPSN US 1.3% 644 323 3.05 1 243 Memory Pharmaceuticals MEMY US 1.4% 1 051 628 0.48 319 Metris MTRS BB 4.5% 563 261 8.95 5 041 Metris warrants - - 425 890 1.64 698 Santhera Pharmaceuticals SANN SW 5.0% 156 192 69.10 6 858 Telenet TNET BB 1.3% 1 415 344 14.00 19 815 Thrombogenics THR BB 0.2% 40 000 7.30 292 Torreypines Therapeutics TPTX US 11.0% 1 738 179 1.36 1 495 Total listed shareholdings 122 650 Loans to companies in the investment portfolio (II) 110 209 Total portfolio (I + II) 848 144 Other assets net of commitments (III) 501 120 Minority interests (IV) 21 710 Equity (attributable to equity holders of the parent company) (I + II + III - IV) 1 327 554 1 Value of Ablynx shares adjusted before lock-up period
GIMV AT A GLANCE AN ACTIVE INVESTOR (2000-<strong>2008</strong> * ) INVESTMENTS EUR 1.4 billion invested in 179 new shareholdings * until 31 March <strong>2008</strong> DIVESTMENTS EUR 1.85 billion divested with 138 exits, 19 IPOs
Page 1 and 2: ANNUAL REPORT 2007 | 2008
Page 3: KEY FIGURES LIMITED CONSOLIDATION 3
Page 7 and 8: Strong performance and expansion in
Page 9 and 10: In 2007-2008 Gimv realised 10 new i
Page 11 and 12: Structure | 08 Strategy | 09 Market
Page 13 and 14: STRATEGY Gimv is an independent, li
Page 15 and 16: Fundraising Provisional fi gures fr
Page 17 and 18: 35000 30000 25000 20000 15000 10000
Page 19 and 20: (EUR 6.6 million), Gimv realised in
Page 21 and 22: Business units Regions Corporate In
Page 23 and 24: When, in the case of a potential sa
Page 25 and 26: Gimv takes 86 percent holding WALL
Page 27 and 28: Gimv accompanies growth through buy
Page 29 and 30: GIMV OFFERS CREDIBILITY ALFACAM GRO
Page 31 and 32: Joint venture of network and experi
Page 33 and 34: Gimv majority shareholder in TerSta
Page 35 and 36: HVEG - (LowLand Fashion) www.lowlan
Page 37 and 38: Corporate Investment Germany (Halde
Page 39 and 40: Gimv invests in world leader VAG DE
Page 41 and 42: Corporate Investment’s ten larges
Page 43 and 44: Overview of major shareholdings in
Page 45 and 46: Oree develops revolutionary lightin
Page 47 and 48: Liquavista www.liquavista.com Dutch
Page 49 and 50: DIVESTMENTS Business Architects www
Page 51 and 52: Overview of the Gimv ICT portfolio
Page 53 and 54: Gimv continues to support sharehold
Page 55 and 56:
GIMV IS A REFERENCE IN THE BIOTECH
Page 57 and 58:
PamGene www.pamgene.com PamGene, a
Page 59 and 60:
Cleantech Last year Gimv took its f
Page 61 and 62:
INVESTMENTS Electrawinds www.electr
Page 63 and 64:
Human resources | 60 Responsible co
Page 65 and 66:
Policy-wise, Gimv is paying ever gr
Page 67 and 68:
RESPONSIBLE CORPORATE BEHAVIOUR You
Page 69 and 70:
Management | 66 Corporate Governanc
Page 71 and 72:
Zeger Collier has had a varied care
Page 73 and 74:
Eric Spiessens is a member of the e
Page 75 and 76:
Paul De Ridder has been a member of
Page 77 and 78:
1.2 - Evolution of capital The capi
Page 79 and 80:
“Prior to the Board of Directors
Page 81 and 82:
Finally the audit committee analyse
Page 83 and 84:
This includes: - joint fi xed remun
Page 85 and 86:
- Rights and duties of shareholders
Page 87 and 88:
10.4 - Threshold for calling a shar
Page 89 and 90:
Volume 16 000 000 14 000 000 12 000
Page 91 and 92:
6 - Dividend policy The Board of Di
Page 93 and 94:
9 - Financial calendar 22 May 2008
Page 95 and 96:
DURING THE 2007-2008 FINANCIAL YEAR
Page 97 and 98:
INTRODUCTION 1. GENERAL INFORMATION
Page 99 and 100:
2. CONSOLIDATED BALANCE SHEET (IN E
Page 101 and 102:
Issued capital Sharepremium account
Page 103 and 104:
6. DIVIDENDS, INTEREST, MANAGEMENT
Page 105 and 106:
Other operating income and expenses
Page 107 and 108:
The distribution of cash and cash e
Page 109 and 110:
STATUTORY CONSOLIDATION 1. CONSOLID
Page 111 and 112:
2. CONSOLIDATED BALANCE SHEET (IN E
Page 113 and 114:
Attributable to shareholders of the
Page 115 and 116:
4. CONSOLIDATED CASH FLOW STATEMENT
Page 117 and 118:
5.9 Property, plant and equipment P
Page 119 and 120:
more appropriate or whether there i
Page 121 and 122:
6. IMPACT OF NEW OR AMENDED STANDAR
Page 123 and 124:
8. SUBSIDIARIES - CONTINUED Informa
Page 125 and 126:
Assets NON-CURRENT ASSETS 31/03/08
Page 127 and 128:
Buy-outs Infrastructure Overhead St
Page 129 and 130:
Buy-outs Infrastructure Overhead St
Page 131 and 132:
Unrealised gains and losses by acti
Page 133 and 134:
14. TAXES (IN EUR 000) 2007-2008 20
Page 135 and 136:
16. PAID AND PROPOSED DIVIDENDS The
Page 137 and 138:
17. GOODWILL EN ANDERE IMMATERIËLE
Page 139 and 140:
19. GOODWILL IMPAIRMENT The goodwil
Page 141 and 142:
22. INVENTORIES (IN EUR 000) Gimv a
Page 143 and 144:
26. PENSION LIABILITIES (IN EUR 000
Page 145 and 146:
Restructuring provision Environment
Page 147 and 148:
29. RELATED PARTIES (IN EUR 000) Ye
Page 149 and 150:
30. FINANCIAL RISK MANAGEMENT See D
Page 151 and 152:
34. OFF-BALANCE SHEET OBLIGATIONS A
Page 153 and 154:
Current liabilities rose by almost
Page 155 and 156:
37. CONNECTION BETWEEN LIMITED AND
Page 157 and 158:
1. BALANCE SHEET AFTER DISTRIBUTION
Page 159 and 160:
GLOSSARY Blue chip: a company that
Page 161 and 162:
Concept & design Concerto Photograp
show all

ANNUAL REPORT 2007 | 2008 - Gimv

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?